Comparative results of 3 treatments for medial femoral condyle subchondral cystic lesions in Thoroughbred racehorses.
Authors: Klein Chelsea E, Bramlage Lawrence R, Stefanovski Darko, Ruggles Alan J, Embertson Rolf M, Hopper Scott A
Journal: Veterinary surgery : VS
Summary
# Medial Femoral Condyle Cystic Lesions: Comparing Three Treatment Approaches in Young Thoroughbreds Subchondral cystic lesions of the medial femoral condyle represent a significant concern in young racehorses, yet optimal treatment remains debated. Klein and colleagues conducted a retrospective analysis of 107 Thoroughbreds under 24 months old treated between 2004 and 2017, comparing three intervention strategies: arthroscopic debridement alone, intralesional autologous mesenchymal stem cell injection, and intralesional corticosteroid injection, with return to racing as the primary outcome measure. Overall, 73% of treated horses raced post-intervention (41/57 debridement, 16/19 MSC, and 21/31 corticosteroid cases), with no statistically significant difference between groups—a finding that may surprise practitioners given the biological appeal of stem cell therapy. Lesion size emerged as the only clinically meaningful predictor, with larger cystic lesions showing a trend towards reduced racing probability, whilst sex and affected limb had no bearing on outcome. These results suggest that practitioners can counsel owners on a generally favourable prognosis across all three modalities (approximately 70–85% return to racing), with treatment selection potentially guided by available resources, cost considerations, and individual case factors rather than anticipated performance differences.
Read the full abstract on PubMed
Practical Takeaways
- •Young Thoroughbreds with MFC subchondral cystic lesions have a good overall prognosis (73% return to racing) regardless of which treatment method is used—choose based on availability and cost rather than expected outcome
- •Larger lesions are less likely to result in racing horses, so use lesion size when counseling owners on realistic expectations
- •All three approaches (arthroscopic debridement, MSC injection, and corticosteroid injection) are viable options; no single method is clearly superior for returning young horses to race
Key Findings
- •73% of Thoroughbreds with MFC subchondral cystic lesions raced post-treatment across all three treatment groups
- •MSC injection showed highest racing success at 84% (16/19), compared to arthroscopic debridement 72% (41/57) and corticosteroid injection 68% (21/31), but differences were not statistically significant
- •Lesion size showed a trend toward reducing probability of racing, but sex, limb affected, and lesion size had no statistically significant effect on ability to start a race
- •All three treatment methods demonstrated good prognosis for racing with no significant difference between groups